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Ovarian cancer is themain cause of death fromgynaecologicalmalignancies. In spite of the efficacy of platinum-paclitaxel treatment
in patients with primary epithelial ovarian carcinoma, platinum-based chemotherapy is not curative and resistance remains one
of the most important causes of treatment failure. Although ABC transporters have been implicated in cellular resistance to
multiple drugs, the clinical relevance of these efflux pumps is still poorly understood. Thus, we examined the prognostic role of
transporters of the MRP family (i.e., ABCC1/MRP1, ABCC4/MRP4) to gain insights into their clinical impacts. A case material of
127 patients with ovarian carcinoma at different stages and histotypes was used. The expression of MRP1 and MRP4 was examined
by immunohistochemistry using tissuemicroarrays in tumor specimens collected at the time of initial surgery expression.We found
an association between MRP1 expression and grading, and we observed that MRP4 displayed an unfavourable impact on disease
relapse in multivariate analysis (HR = 2.05, 95% CI: 1.01–4.11; 𝑃 = 0.045). These results suggest that in epithelial ovarian cancer,
MRP1may be amarker for aggressiveness because its expression was associated with tumor grade and support that MRP4may play
an unfavourable role in disease outcome.
1. Introduction
Ovarian cancer is themain cause of death from gynecological
malignancies and the majority of epithelial ovarian tumors
are diagnosed as advanced stage diseases [1]. Recent studies
have shown that ovarian carcinoma is a complex disease that
gathers molecularly different tumors sharing the localiza-
tion more than biological features [2]. The management of
ovarian carcinoma includes cytoreductive surgery, followed
by platinum (carboplatin or cisplatin) taxane chemotherapy,
which has become a standard treatment for advanced stage
disease [3, 4]. In spite of the efficacy of the platinum-paclitaxel
combination with responses observed in at least three quar-
ters of the patients, the outcome is poor and responses
are incomplete. The limited efficacy of chemotherapy may
be dependent on the expression of defence factors which
confer increased survival potential for tumor cells and, as a
consequence, a multidrug resistant phenotype [5].Therefore,
an analysis of the expression by tumor cells ofmembers of the
ATP Binding Cassette (ABC) efflux transporter superfamily
may be useful and could help in the choice of treatments
defined on the basis of the molecular features of the tumor.
Whole-genome approaches have documented the exis-
tence of a wide family of ABC transporters, including 50
different members that can be grouped into seven distinct
classes based on sequence similarities [6, 7]. Whereas it has
been clearly established that ABCB1 and ABCG2 do not
confer resistance to platinum compounds, selected members
of the ABCC/MRP family have been implicated in resistance
to platinum compounds and taxanes [8, 9]. The notion that
ABC transporters are a large family of genes supports the
need for novel studies directed at clarifying the relationship
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between less characterized transporters and resistance. Also,
the recent knowledge achieved by integrating biochemical
and molecular approaches indicates that the investigation of
expression of ABC transporters in large collections of tumor
specimens should be pursued in an attempt to elucidate the
role of such factors in tumor biology. In fact, ABC transporter
expression has been linked to tumor aggressiveness in differ-
ent tumor types [10].
In a cellular study, cells resistant to platinum compounds
were found to display increased levels ofMRP1 andMRP4 [9].
In addition, the available evidence supports that the effects
of transporters of the MRP subfamily on cell survival may
be indirect, not necessarily implicating only efflux of the
cytotoxic drugs [8]. In this regard,MRP4has been involved in
signalling pathways which activate prosurvival mechanisms
by virtue of its capability to pump cyclic nucleotides outside
the cells [11].
Based on this background, to document the role of MRP1
and MRP4 in the clinical setting in ovarian carcinoma, we
investigated the role of MRPs as prognostic markers for
this tumor using archival material from tumor specimens
collected at surgery from epithelial ovarian carcinoma (EOC)
patients.
2. Material and Methods
2.1. Patients, Tissue Specimens, and Pathologic Data. This
study was performed on a tissue microarray (TMA) con-
taining a series of formalin-fixed, paraffin-embedded tissues
collected at surgery before any chemotherapeutic treatment
from 127 consecutive EOC patients who underwent surgical
resection at the S. Chiara Hospital in Trento between 1992
and 1999 [12]. Histological sections and paraffin blocks
were obtained from the Hospital Department of Pathology.
Clinical data and follow-up information were available from
theUnit of GynecologicOncology as specified in institutional
follow-up procedures. The use of tissue blocks and patient
records was approved by the Institutional Review Board. All
patients gave informed consent for the therapy and for the use
of specimens for research.
Table 1 summarizes the patients’ clinicopathological char-
acteristics. The average age of the patients was 58 years.
Tumor staging was in accordance with International Feder-
ation of Gynecology and Obstetrics (FIGO) criteria; 31% of
patients had stage I-II and 68% of patients had stage III-IV
disease. Most tumors were of serous histotype (65%). Forty-
five percent of the cases were low grade (well moderately
differentiated) and 52% were high-grade tumors (poorly
differentiated, undifferentiated). Primary treatment for all
patients was surgery, and based on the extent of residual
disease after primary surgery, the patient population was
divided into three groups: no evident disease (NED),minimal
residual disease (mRD, residual tumor smaller than 1 cm)
and gross residual disease (GRD, residual tumor equal/grater
than 1 cm), [13]. Residual disease after surgical debulking was
defined for 112 patients and was optimal (not evident disease
or below 1 cm) in 52% of cases and equal/greater than 1 cm
Table 1: Patient’s clinical characteristics.
Characteristics Patients (𝑛 = 127)
N∘ %
Age, years
(mean, median 58; range 23–84)
Tumor histotype
Serous 83 65
Undifferentiated 12 10
Clear cell 12 10
Endometrioid 12 10
Mucinous 6 4
Others + mixed 2 1
Tumor stage (FIGO)
I 24 19
II 15 12
III 64 50
IV 23 18
Not available 1 1
Tumor grade
1: well differentiated 9 7
2: moderately differentiated 48 38
3: poorly differentiated 53 42
Undifferentiated 12 10
Not available 5 3
Amount of residual disease
NED 47 37
<1 cm 19 15
>1 cm 46 36
Not available 15 12
Frontline treatment
None 8 6
Platinum without taxanes 81 64
Platinum/paclitaxel 35 28
Other or not available 3 2
Response to frontline treatment∗
Complete 57 46
Partial 21 18
No response 21 18
Not available 21 18
Abbreviations: FIGO: International Federation of Gynecological andObstet-
rics staging system. NED: not evident disease. ∗Untreated patients are not
included.
in 36% of cases. After surgery, 119 patients received front-
line treatment with standard platinum-based therapeutic
schedules (platinum without taxanes; platinum and pacli-
taxel) according to the time of accrual/year of diagnosis; two
patients were treated with other chemotherapeutic agents,
eight patients (all stage I) received no chemotherapy, and
one patient had information missing. Response to therapy
was available for 99 patients. Response was based on data
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from medical records, instrumental evaluation, and Ca 125
levels and was scored as complete (57 cases), partial (disease
reduced by 50%) (21 cases), or absent (21 cases) according
to the WHO standard criteria [14]. Remission was defined
after completion of first-line treatment as disappearance of
all clinical, radiological, and biochemical evidence of EOC.
Follow-up time was based on patient date of death or the
last information available in themedical records.Themedian
of follow-up period for all patients was 89 months. Time
to progression (TTP) was calculated as the time in months
from the date of surgery until the first evidence (clinical,
instrumental, or biological) of disease progression.
2.2. Immunohistochemistry. MRP expression was exam-
ined by immunohistochemistry (IHC) on formalin-fixed,
paraffin-embedded sections of EOC TMA. Briefly, after
xylene deparaffinization and alcohol rehydration, sections
were subjected to antigen retrieval in 10mM, pH 6.0, citrate
buffer at 95∘C for 6min and 15min in autoclave forMRP4 and
MRP1, respectively. Endogenous peroxidasewas quenched by
incubating the slide with 3%H
2
O
2
for 10min. After washing,
slides were incubated in saturating solution (PBS 1% BSA) for
30min at room temperature (RT), followed by 1-hour incuba-
tion at RT with primary rat monoclonal anti-MRP1 (MRPr1,
MONOSAN) orMRP4 (M4 I-80, MONOSAN) antibody at a
1 : 20 dilution. Afterwashing, slideswere incubated for 30min
at room temperature with biotinylated anti-rat secondary
antibody (1 : 200, Dako S.p.A, Milan, Italy) followed by HPR-
streptavidin for 30min at room temperature. The peroxidase
reaction was developed with 3, 3󸀠-diaminobenzidine (Dako),
and sections were counterstained with hematoxylin. Slides
incubated with secondary antibody alone provided negative
controls.The IHC experimental protocol was set up using the
IGROV-1 cell line, which expressesMRP1 andMRP4 proteins
as observed through Western blotting.
Staining was recorded by a semiquantitative grading
system. Samples were defined as positive when 10% of cells
displayed reactivity. Slides were evaluated by two indepen-
dent observers blinded to patient characteristics and out-
come. All cases with discrepant evaluations were discussed
during observation with a double-headed microscope, and a
consensus was reached.
2.3. StatisticalMethods andDataAnalysis. Subsets of patients
were grouped based on similar clinical-pathological parame-
ters (see Tables 1, 2, 3, 4, and 5). Fisher’s test or 𝜒2 test was
used to analyze the distribution of MRP positive cases in
relation to clinical and pathological category variables. The
effects of MRPs’ expression on time to progression (TTP)
were investigated first by univariate analysis through the
inspection of Kaplan-Meyer curves and differences between
curves were assessed for statistical significance using the log-
rank test.
A Cox univariate model was used to estimate the hazard
ratio (HR) for each prognostic variable considered. Multi-
variable analysis using a Cox regression model was used to
evaluate the prognostic impact of MRPs expression in the
context of concomitant effects of other known prognostic
factors. Frontline therapy was used as a stratification factor
accounting for its possible nonproportional effect. The 𝑃 val-
ues of all statistical tests were 2 sided. For all analyses, differ-
ences were considered significant at𝑃 lower than 0.05. Analy-
ses were performed with the GraphPad Software version 3.03
and R statistical language (URL: http://www.R-project.org/).
3. Results
3.1. Expression of MRP1 and MRP4 in Primary Epithelial
Ovarian Carcinoma. To investigate the expression of ABC
transporters in ovarian cancer tissues, tumor specimens were
analyzed by IHC. In tumor specimens, the MRP1 and MRP4
specific staining mainly displayed a cytoplasmic localization
consistent with localization at subcellular membranes (Fig-
ures 1 and 2). The cytoplasmic immunoreactivity frequently
displayed a granular aspect, similar to what is observed in cell
lines using immunofluorescence (data not shown).Overall, in
specimens, the staining intensity was more intense for MRP1
than for MRP4, a feature that may reflect tumor biology.
Thirty percent of assessable tumors were MRP1 reactive
and 23% were MRP4 reactive. An analysis of the association
betweenMRP1 orMRP4 expression and known clinical prog-
nostic factors indicated a statistically significant association
between tumor grade and MRP1 expression (𝜒2 = 8.47; 𝑃 =
0.037, Table 2). No correlation with other clinicopathological
characteristics was observed.
MRP1 and MRP4 expression was concurrently assessable
for 101 cases. AmongMRP1 negative tumors, only 14% (10 out
of 84) were MRP4 positive, whereas among MRP1 positive
cases 47% (13 out of 36) were MRP4 positive (𝜒2 = 10.5;
𝑃 = 0.0011). Then, the fraction of tumors positive for both
transporters was 14% (13 out of 101 cases; Table 3).
3.2. Relationship between Prognostic Variables and MRP1 or
MRP4. In an attempt to define the prognostic impact of
MRP1 and MRP4 on TTP, we performed univariate analyses
to seek for associations. Since a low number (𝑛 = 9) of
tumors with a G1 grade was available in the present case
material, analyses were carried out without including such
cases (Table 4). As expected, the analyses indicated that
known clinical prognostic factors (such as advanced stage III-
IV versus I-II), histotype (serous versus others), and residual
tumor after surgical debulking were associated with shorter
TTP in high-grade EOC informative cases (Table 4). Using
this approach, we found that neither MRP1 nor MRP4 was
significantly associated with TTP.
We then appliedmultivariable Cox regressionmodel with
MRP1 and MRP4 expression adjusting for all known clinical
and pathological prognostic factors. In this model, well-
established clinical prognostic factors (stage and residual
disease) maintained their unfavourable prognostic impact.
MRP1 did not display any prognostic impact, whereas that
of MRP4 was unfavourable (HR = 2.05, 95% CI: 1.01–4.11;
𝑃 = 0.045).
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Table 2: Patient’s clinical and pathological characteristics according to MRP1 and MRP4 expression as assessed by immunohistochemistry.
Clinical parameters
Total
(𝑛 = 127)
MRP1 expression MRP4 expression
Negative (𝑛 = 84) Positive (𝑛 = 36) Missing(𝑛 = 7) 𝑃∗ Negative (𝑛 = 80) Positive (𝑛 = 24)
Missing
(𝑛 = 23) 𝑃∗
N∘ % N∘ % N∘ % N∘ %
Age, years 0.245 0.971
≤55 40 75 13 25 2 33 77 10 23 12
>55 44 66 23 34 5 47 77 14 23 11
Tumor histotype 0.617 0.686
Serous 53 68 25 32 5 52 74 18 26 13
Undifferentiated 9 82 2 18 1 7 87 1 13 4
Clear cell 8 67 4 33 10 83 2 17
Endometrioid 8 67 4 33 6 67 3 33 3
Mucinous 5 100 1 3 100 3
Others 1 50 1 50 2 100
Tumor stage (FIGO) 0.178 0.172
I + II 30 79 8 21 1 30 83 6 17 3
III 40 69 18 31 6 36 78 10 22 18
IV 13 57 10 43 13 62 8 38 2
Missing 1 1
Tumor grade 0.037 0.821
1 7 78 2 22 5 83 1 17 3
2 37 80 9 20 2 32 74 11 26 5
3 27 55 22 45 4 31 74 11 59 11
Undifferentiated 9 82 2 18 1 7 87 1 13 4
Missing 4 1 5
Amount of residual
disease 0.32 0.29
NED 33 75 11 25 3 31 82 7 18 9
<1 cm 12 67 6 33 1 10 62 6 38 3
>1 cm 27 60 18 40 1 26 70 11 30 9
Missing 12 1 2 13 2
NED: not evidence of disease. ∗𝑃 values: evaluated on MRP1 and MRP4 expression and available clinical and pathological parameters.
4. Discussion
Preclinical evidence supports that the expression of MRP1
and MRP4 is increased in ovarian carcinoma cells character-
ized by resistance to platinum compounds [9]. Furthermore,
we have previously shown that lung cancer CD133+ cells,
which are spared by cisplatin treatment in xenografted lung
cancer models, are enriched in ABC transporters, including
MRP1 and MRP4 [15]. Thus, the present study was designed
to examine the expression of MRP1 and MRP4 on archival
material from EOC patients with known clinical history. IHC
was chosen as a method with the specific aim to set up proce-
dures potentially useful for prospective clinical studies first,
and then for routine analysis of tumor specimens. Also, we
elected to use TMA because they provide a high-throughput
technique for the molecular profiling of tissue specimens
strengthened by the availability of sequentially sliced samples
from the same master block to test the expression of the
relevant macromolecules [16].
Given the function of drug transporters and their capa-
bility to extrude from cells toxins, drugs, and physiological
substrates [8], a clear definition of their prognostic role is not
straightforward to achieve. The available evidence supports
that the ABC transporters MRP1 and MRP4 were shown to
display an unfavorable prognostic impact on neuroblastoma
[17, 18]. Also, in this tumor type, a prognostic value for MRP1
has been clearly documented by carrying out a prospective
study [18].
In the present retrospective study, the prognostic impact
was evaluated in terms of progression-free survival which,
by being an earlier end point than overall survival, was
considered more appropriate when modelling the prognostic
significance of drug transporters which are expected to
influence treatment outcome and to control drug efficacy.
BioMed Research International 5
Table 3: MRP1 versus MRP4 expression in EOC as assessed by
immunohistochemical staining.
MRP1
expression
MRP4 expression 𝜒2
(P-value)Negative
80
Positive
24
Not available
23
Negative
84 63(86%)∗ 10 (14%) 11
Positive
36 15 (54%) 13 (47%) 8 10.536
Not available
7 2 1 4 0.0011
∗Raw percentages are reported and refer to the only case valuable for both
MRPs.
Table 4: Univariate analysis of the prognostic impact of clinical
covariates and MRPs on progression-free survival in high-grade
EOC.
𝑃
∗ HR (95% CI)
Stage
III-IV versus I-II <0.0001 7.78 3.85–15.7
Histotype
Serous versus
others 0.011 1.9 1.16–3.12
Surgical debulking
SOD versus OD <0.0001 3.4 2.09–5.52
Age at diagnosis
>55 versus ≤55 0.48 1.17 0.76–1.8
MRP1 expression
Positive versus
negative 0.86 0.96 0.6–1.53
MRP4 expression
Positive versus
negative 0.27 1.35 0.8–2.28
∗
𝑃 value determined using log-rank test; HR: hazard ratio; CI: confidence
interval; SOD: suboptimal debulking (residual disease >1 cm), OD: optimal
debulking (residual disease not evident or <1 cm).
Indeed, overall survivalmay be dependent on amultiplicity of
variables, not necessarily on expression of drug transporters.
In fact, EOC patients resistant to first-line chemotherapy
(around 30%) as well as patients that experienced disease
relapse after successful first-line chemotherapy (around 70%
of sensitive patients) [19] receive further chemotherapy reg-
imen, including different agents with a variable pattern of
recognition by ABC transporters.
Considering disease relapse as the clinical end point
of our analysis, an unfavorable role for the expression of
MRP4 was also observed in this case material, whereas this
behaviour was not found for MRP1. Here, we also found an
association between MRP1 expression and tumor grade. This
observation is at least in part in keeping with a paper report-
ing expression ofMRP1 in aggressive ovarian carcinoma [20].
In fact, significantly increased MRP1 protein expression was
Table 5: Multivariable analysis of the prognostic impact of clinical
covariates and MRPs on progression free survival in high-grade
EOC.
𝑃
∗ HR (95% CI)
Stage
III-IV versus I-II <0.0001 10.5 3.56–30.8
Histotype
Serous versus
others 0.96 0.98 0.47–2.05
Surgical debulking
SOD versus OD 0.016 2.22 1.16–4.26
Age at diagnosis
>55 versus ≤55 0.07 0.57 0.3–1.3
MRP1 expression
Positive versus
negative 0.11 0.58 0.31–1.13
MRP4 expression
Positive versus
negative 0.045 2.05 1.01–4.11
∗P value determined using log rank test; HR: hazard ratio; CI: confidence
interval; SOD: suboptimal debulking (residual disease >1 cm), OD: optimal
debulking (residual disease not evident or <1 cm).
observed in high-grade tumors, similar to the present study.
However, the case material used by Faggad and coauthors
is not representative of the standard clinical behaviour of
this disease regarding survival rate and prognostic impact
of clinical variables (e.g., stage). Here, we did not find an
association between disease stage and MRP1, and patients
with higher expression of MRP1 protein did not exhibit
significantly decreased overall survival (data not shown).
Although our data validate only in part the previous findings,
the discrepancies may be due to the different features of the
two casematerials. However, the bottom line of these findings
is that less differentiated cells express the MRP1 protein. Of
note, MRP1 levels have been shown to correlate with grading
in untreated hepatocellular carcinoma [21]. The association
between MRP1 and grading suggests an aggressive nature of
theMRP1 expressing tumors. Since less differentiated tumors
are expected to be endowed with the greatest proliferation
potential, thereby being chemoresponsive, the unfavourable
role of MRP1 may be difficult to assess. Thus, the prospective
collection of a more homogeneous case material with respect
to this pathologic parameter (i.e., grading) may be helpful in
designing the prognostic role of MRP1 in disease relapse.
5. Conclusion
In the present study, using a case material containing ovarian
carcinoma specimens, we found an association between
MRP1 and grading and we observed that MRP4 displayed an
unfavourable role in disease outcome. However, additional
effort is required to better understand the precise mechanism
by which MRP1 and MRP4 may influence tumor biology
and drug resistance in an attempt to rationally develop
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(a) (b)
Figure 1:MRP1 immunostaining in specimens of ovarian carcinoma. Immunostaining decoratesmost of tumor cells of an ovarian carcinoma.
MRP1 displayed a cytoplasmic localization consistent with cellular localization at subcellular membranes. Cytoplasmic immunoreactivity
frequently displayed a granular aspect.
(a) (b)
(c)
Figure 2: MRP4 immunostaining in specimens of ovarian carcinoma. MRP4 displayed a cytoplasmic localization consistent with cellular
localization at subcellular membranes. Cytoplasmic immunoreactivity frequently displayed a granular aspect.
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therapeutic options including combination therapies based
on the use of modulators of ABC transporters [22] or drugs
that are not substrates for such efflux pumps [8].
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